¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Alpha cell, pancreatic"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • mononuclear cell
    ´ÜÇÙ¼¼Æ÷, ´ÜÇÙ±¸
  • mossy cell
    À̳¢¼¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • motor cell
    ¿îµ¿½Å°æ¼¼Æ÷
  • mucous cell
    Á¡¾×¼¼Æ÷
  • mulberry cell
    ¿Àµð¼¼Æ÷
  • multinuclear giant cell
    ´ÙÇÙ°Å´ë¼¼Æ÷, ¹µÇÙ°Å´ë¼¼Æ÷
  • multipolar nerve cell
    ´Ù±Ø½Å°æ¼¼Æ÷, ¹µ±Ø½Å°æ¼¼Æ÷
  • myeloid cell
    °ñ¼ö¼¼Æ÷
  • myeloma cell
    °ñ¼öÁ¾¼¼Æ÷
  • myoepithelial cell
    ±Ù(À°)»óÇǼ¼Æ÷
  • myoid cell
    ±Ù(À°)À¯»ç¼¼Æ÷
  • mantle cell lymphoma
    ¿ÜÅõ¼¼Æ÷¸²ÇÁÁ¾
  • marrow cell
    °ñ¼ö¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • pilomotor cell
    Åп½Å°æ¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • pluripotential cell
    ´Ù´É¼º¼¼Æ÷
  • polyhedral cell
    ¹µ¸éü¼¼Æ÷
  • polynucleated cell
    ¹µÇÙ¼¼Æ÷
  • prickle cell
    °¡½Ã¼¼Æ÷
  • primed cell
    ÃÊȸ°¨ÀÛ¼¼Æ÷
  • primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
  • principal cell
    ÁÖ¼¼Æ÷
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷, Á¶·Õ¹Ú¼¼Æ÷
  • pyramidal cell
    ÇǶó¹Ô¼¼Æ÷
  • receptor cell
    ¼ö¿ëü¼¼Æ÷
  • red blood cell
    ÀûÇ÷±¸
  • reserve cell
    ¿¹ºñ¼¼Æ÷
  • residential cell
    Á¤ÁÖ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´, Åм¼Æ÷¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷ ¹éÇ÷º´
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷ ¹éÇ÷º´
  • hairy-cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷(¡­á¬øà)
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper T cell
    Á¶·ÂT¼¼Æ÷, º¸Á¶T¼¼Æ÷
  • helper T cell
    º¸Á¶ T¼¼Æ÷
  • helper T cell
    º¸Á¶ T ¼¼Æ÷
  • helper cell
    º¸Á¶¼¼Æ÷
  • helper cell
    Á¶·Â¼¼Æ÷, º¸Á¶¼¼Æ÷
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä(¡­á¬øàì¹ãÕ)
  • hematopoietic stem cell
    Á¶Ç÷°£¼¼Æ÷
  • hemolytic plaque-forming cell
    ¿ëÇ÷¹Ý Çü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ© Çü¼º¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • budding cell
    ¹ß¾Æ¼¼Æ÷(¡­á¬øà).
  • budding cell
    ¹ß¾Æ¼¼Æ÷(¡­á¬øà).
  • burr cell
    À¯±ØÀûÇ÷±¸
  • cameloid cell
    Ÿ¿øÇüÀûÇ÷±¸(¡­îåúìϹ).
  • cancer cell
    ¾Ï¼¼Æ÷ (äßá¬øà)
  • capsule cell
    ÇǸ·¼¼Æ÷(¡­á¬øà), À§¼º¼¼Æ÷.
  • carcinoma, spindle cell
    ¹æÃ߻󼼯÷ ¾ÏÁ¾
  • carcinoma,renal cell
    ½Å ¼¼Æ÷ (ãìá¬øà)
  • carcinoma,squamous cell
    ÆíÆò»óÇǾÏÁ¾(ø·øÁß¾ù«äßðþ)
  • cardiac muscle cell
    ½ÉÀå±ÙÀ°¼¼Æ÷
  • caterpillar cell
    ¸ðÃæ ¼¼Æ÷(Ù¾õùá¬øà)
  • cell
    ¼¼Æ÷(á¬øà)
  • cell
    ¼¼Æ÷
  • cell adhesion molecular deficiency
    ¼¼Æ÷À¯ÂøºÐÀÚ°áÇÌ
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
AHSG alpha-2HS-glycoprotein
'Greek letter alpha' angular acceleration; first [carbon atom next to the carbon atom bearing the active group in organic...
alpha2-AP alpha 2-antiplasmin
AMD acid maltase deficiency; acromandibular dysplasia; actinomycin D; adrenomyelodystrophy; age-related ...
A2MG alpha-2-macroglobulin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
alpha-MSH Alpha-Melanocyte stimulating hormone
alpha-MPT alpha-methyl-L-p-tyrosine
alpha-TH Alpha-Tocopherol
alpha-AAA DL-alpha-aminoadipic acid
alpha-DTx Alpha-dendrotoxin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multinucleated giant cell
    ´ÙÇÙ °Å´ë ¼¼Æ÷, °Å´ë ´ÙÇÙ ¼¼Æ÷, ´ÙÇÙ °Å¼¼Æ÷
  • multipolar nerve cell
    ¹µ ±Ø ½Å°æ ¼¼Æ÷, ´Ù±Ø ½Å°æ ¼¼Æ÷
  • muscle cell
    ±Ù ¼¼Æ÷
    ´Éµ¿ÀûÀ¸·Î ¼öÃ༺À» º¸ÀÌ´Â µ¿¹°Ã¼³»ÀÇ ¼¼Æ÷. ±ÙÀ° ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ±Ù Á¶Á÷À» ±¸¼ºÇÏ´Â °æ¿ì °¢°¢ÀÇ ±Ù ¼¼Æ÷´Â ÀϹÝÀûÀ¸·Î ¹æÃß»ó ¶Ç´Â ¼¶À¯»óÀ» ¶í´Ù. ÇØ¸éµ¿¹°Àº ±ÙÁ¶Á÷ÀÌ ¾øÀ¸³ª, ±Ô°¢ ÇØ¸é·ù¿¡¼­´Â üǥÀÇ ÆíÆò»óÇÇ ¼¼Æ÷°¡ ¾ó¸¶°£ ¼öÃ༺À» °¡Áö¸ç, üǥ ƯÈ÷ À¯Ãâ°ø ÁÖº¯¿¡ ¹Ì¿À»çÀÌÆ®¶ó°í ÇÏ´Â ±ä ¹æÃßÇüÀÇ ¼öÃ༺ ¼¼Æ÷°¡ Á¸ÀçÇÑ´Ù. ¶Ç ¼®È¸ ÇØ¸é·ùÀÇ ¼Ò°ø ¼¼Æ÷¿¡µµ ¼öÃ༺ÀÌ ÀÎÁ¤µÈ´Ù. À̵éÀº ¾î¶² Á¾·ùÀÇ ¿ø»ýµ¿¹° ¸ö Àüü¿¡ ³ªÅ¸³ª´Â ¼öÃ༺°ú ´õºÒ¾î ±Ù ¼¼Æ÷°¡ ³ªÅ¸³ª´Â ½ÃÀÛ ÇüÅ·Π°£ÁֵȴÙ. °­À嵿¹°ÀÇ Æú¸³Çü¿¡¼­´Â ¿Ü¹è¿± ¼¼Æ÷ Ãþ ¼Ó¿¡ ÀÖ´Â »óÇÇ ±Ù ¼¼Æ÷¿¡ ÁøÁ¤ÇÑ ±Ù¿ø¼¶À¯°¡ ÀÖ´Ù. À̰ÍÀº °¡Àå ÈçÈ÷ ÀÖ´Â ¿øÁÖ»óÇÇ ¼¼Æ÷, ÁïÁöÁö ¼¼Æ÷ÀÇ ±âÀúºÎ°¡ ¹æÃßÇüÀ¸·Î ´Ã¾î³ª¼­ ±× ºÎºÐ¿¡ ÇÑÇØ¼­ ±Ù¿ø¼¶À¯°¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î, üǥÀÇ »óÇÇ ¼¼Æ÷¿¡¼­ ±Ù¼¼Æ÷·Î ºÐÈ­ÇÏ´Â µµÁßÀÇ °ÍÀÌ´Ù. ÇØÆÄ¸® Çü¿¡¼­´Â ¹æÃßÇü ±Ù ¼¼Æ÷°¡ ¿Ï¼ºµÈ´Ù. ÆíÇüµ¿¹° À̻󿡼­´Â ÇDZÙÃþ, ±â°ü±Ù µî ºÐÈ­°¡ ÇöÀúÇÏ´Ù.
  • muscle-cell
    ±Ù ¼¼Æ÷
  • mycosis cell
    ¸¶ÀÌÄڽýº ¼¼Æ÷, Áø±Õ ¼¼Æ÷
    ¸¹Àº ºñÁ¤Çü ¸²ÇÁ°è ¼¼Æ÷ÀÇ Çϳª·Î¼­ °ú¿°»ö¼ºÀÇ ½ÉÇÑ È¸¼±»ó ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ¿øÁ¶/À¯µµ ¼¼Æ÷ Ç¥ÇöÇüÀÇ T ¼¼Æ÷¿¡¼­ À¯·¡ÇÑ °ÍÀ¸·Î º¸ÀδÙ. ¿ë»ó Áø±ÕÁõ¿¡¼­ »óÇdzª ÆÄ¿ìÆ®¸®¾î
  • myoid cell
    ±ÙÀ°¾ç ¼¼Æ÷
  • natural kil1er cell
    ÀÚ¿¬ »ì¼¼Æ÷
    ¼±Ãµ¼º ¸é¿ªÀÇ Áß¿ä ÀÎÀÚ. ¼¼Æ÷ ³»¿¡ azuro
  • nerre cell body
    ½Å°æ¿øÃ¼, ½Å°æ ¼¼Æ÷ü
  • nerve cell
    ½Å°æ ¼¼Æ÷
    ´º·±¿¡¼­ µ¹±â¸¦ Á¦¿ÜÇÑ ºÎºÐ. ³ÐÀº Àǹ̷δ ´º·±°ú °°Àº ¶æÀ¸·Î ¾²ÀÌÁö¸¸ Á¼Àº Àǹ̷Π½Å°æ ¼¼Æ÷¸¦ ¼¼Æ÷ü
  • nerve cell layer
    ½Å°æ ¼¼Æ÷ Ãþ
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷, ½Å°æ ±³¼¼Æ÷
  • neuronal cell membrane
    ´º¿ì·± ¼¼Æ÷¸·
  • nh-cell ; °©»ó¼± ¹æ¿¡ ÀÖ´Â °ÍÀ¸·Î °¡Á¤µÇ´Â ½Å°æ È£¸£¸ó ¼¼Æ÷.

    Ni

    ´ÏÄÌ
    nickelÀÇ ¿ø¼Ò ±âÈ£.
  • Niemann Pick's cell
    ´Ï¸¸-ÇÇÅ© ¼¼Æ÷
    ·¹½ÃƾÀ» ´Ù·®À¸·Î ÇÔÀ¯ÇÏ´Â ¼¼Æ÷.
  • nociceptive dorsal horn cell
    Ä§ÇØ ¼ö¿ë¼º Èİ¢ ¼¼Æ÷, À¯ÇØ ¼ö¿ë¼º Èİ¢ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
D-selenocystine alpha, beta-lyase <enzyme> From clostridium sticklandii; pyridoxal-p enzyme; mw 74kda; decomposes d-selenocystine into pyruvate, nh3 and elemental selenium; d-cystine, d-lanthionine, meso-lanthionine and d-cysteine can also serve as substrates; d-selenocysteine, d-serine, dl-selenohomocystine and l-amino acids are inert
Registry number: EC 4.99.-
Synonym: dsc-ab-lyase
(26 Jun 1999)
I kappa B alpha-associated protein kinase <enzyme> Isolated from human monocytic cell line; phosphorylates ser(293), ser(288), and thr(291) of ikappabalpha
Registry number: EC 2.7.10.-
Synonym: ikappabalpha-associated protein kinase, ikappab-alpha-associated protein kinase, ikappabalpha kinase
(26 Jun 1999)
immunoglobulins, alpha-chain Heavy chains found in the fab and fc fragments of IgA and having a molecular weight of approximately 58 kD. They contain about 470 amino acid residues arranged in four domains and an oligosaccharide component bound covalently to the fc fragment.
(12 Dec 1998)
indolyl-3-alkane-alpha-hydroxylase <enzyme> Indoyl-3-alkane-alpha-hydroxylase; haemprotein which needs no cofactor
Registry number: EC 1.13.99.-
Synonym: tryptophan side chain oxidase
(26 Jun 1999)
inositol 1-alpha-galactosyltransferase <enzyme> Catalyses conversion of udpgalactose plus myo-inositol to galactinol plus udp
Registry number: EC 2.4.1.123
Synonym: galactinol synthase
(26 Jun 1999)
inter-alpha-inhibitor <chemical> Inhibits bovine trypsin and chymotrypsin; complex formed with chymotrypsin less stable; alpha-glycoprotein; shap - serum-derived hyaluronan associated protein
Pharmacological action: serine proteinase inhibitors, trypsin inhibitors
Chemical name: trypsin inhibitor, inter-alpha-
Synonym: inter-alpha-trypsin inhibitor, protein pi, inter-alpha-trypsin inhibitor, heavy chain, shap protein
(05 Dec 1998)
interferon-alpha <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products.
It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia.
A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents.
See: interferon-alpha 2a, interferon-alpha 2b
Synonym: leukocyte interferon.
Pharmacological action: antineoplastic agent, antiviral agent.
(20 Sep 2002)
interferon-alpha 2a <cytokine> Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-alphaA (human leukocyte protein moiety reduced)
(12 Dec 1998)
interferon-alpha 2b <chemical> Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
testosterone 15-alpha hydroxylase <enzyme> A haem-thiolate protein (cytochrome p-450)
Registry number: EC 1.14.15.-
Synonym: cytochrome p-450(15alpha), testosterone 15-alpha monooxygenase, steroid 15-alpha-hydroxylase, cytochrome p-4502a-4, cyp2a-4, cyp2a4
(26 Jun 1999)
testosterone 5-alpha-reductase <enzyme> Chemical name: 3-Oxo-5 alpha-steroid:(acceptor) delta(4)-oxidoreductase
Registry number: EC 1.3.99.5
(12 Dec 1998)
TM-1 alpha-fibrinogenase <enzyme> Isolated from the venom of taiwan habu, trimeresurus mucrosqamatus
Registry number: EC 3.4.24.-
(26 Jun 1999)
TM-2 alpha-fibrinogenase <enzyme> Isolated from the venom of taiwan habu, trimeresurus mucrosquamatus
Registry number: EC 3.4.24.-
(26 Jun 1999)
TM-3 alpha-fibrinogenase <enzyme> Isolated from the venom of taiwan habu, trimeresurus mucrosquamatus
Registry number: EC 3.4.24.-
(26 Jun 1999)
endo-1,3-alpha-glucanase <enzyme> Endohydrolysis of 1,3-alpha-d-glucosidic linkages in isolichenin, pseudonigeran and nigeran; may also be called mutanase, see EC 3.2.1.84 exo-1,3-alpha-glucanase
Registry number: EC 3.2.1.59
Synonym: endo-1,3-alpha-d-glucanase, endo-alpha-1,3-glucanase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á